Spots Global Cancer Trial Database for therapeutic autologous lymphocytes
Every month we try and update this database with for therapeutic autologous lymphocytes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | NCT00324623 | Melanoma (Skin) | Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Centre Hospitalier Universitaire Vaudois | |
| Biological Therapy in Treating Patients With Prostate Cancer | NCT00039299 | Prostate Cancer | therapeutic aut... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | NCT00022230 | Breast Cancer | aldesleukin filgrastim sargramostim therapeutic aut... cyclophosphamid... doxorubicin hyd... paclitaxel | 18 Years - | Roger Williams Medical Center | |
| Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT00466531 | Leukemia | therapeutic aut... cyclophosphamid... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | NCT01339663 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... aldesleukin autologous tumo... laboratory biom... immunologic tec... immunohistochem... polymerase chai... therapeutic aut... | 18 Years - | Fred Hutchinson Cancer Center | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | NCT00553306 | Recurrent Melan... Stage IV Melano... | therapeutic aut... aldesleukin cyclophosphamid... biopsy immunohistochem... flow cytometry polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | NCT00004022 | Melanoma (Skin) | aldesleukin autologous tumo... muromonab-CD3 therapeutic aut... surgical proced... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | NCT00019084 | Breast Cancer Cervical Cancer Colorectal Canc... Lung Cancer Ovarian Cancer Pancreatic Canc... | aldesleukin mutant p53 pept... ras peptide can... sargramostim therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer | NCT00020722 | Breast Cancer | therapeutic aut... Ifosfamide, car... Cyclophosphamid... Leukapheresis peripheral bloo... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | NCT00019357 | Unspecified Adu... | aldesleukin therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | NCT00945269 | Recurrent Melan... Stage III Melan... Stage IV Melano... | therapeutic aut... aldesleukin denileukin dift... biopsy immunohistochem... laboratory biom... polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | NCT00324623 | Melanoma (Skin) | Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Centre Hospitalier Universitaire Vaudois | |
| Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer | NCT00030342 | Colorectal Canc... Kidney Cancer | recombinant int... sargramostim therapeutic aut... fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | NCT00621452 | B-cell Chronic ... Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac... | therapeutic aut... cyclophosphamid... aldesleukin polymerase chai... gene rearrangem... lymph node biop... genetically eng... bone marrow asp... flow cytometry laboratory biom... enzyme-linked i... | - | Fred Hutchinson Cancer Center | |
| Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme | NCT00331526 | Brain and Centr... | aldesleukin therapeutic aut... adjuvant therap... conventional su... | 16 Years - | Hoag Memorial Hospital Presbyterian | |
| Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma | NCT00006480 | Neuroblastoma | aldesleukin therapeutic aut... chemotherapy ganciclovir | 1 Year - 17 Years | Fred Hutchinson Cancer Center | |
| Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00079144 | Melanoma (Skin) | NY-ESO-1 peptid... aldesleukin filgrastim incomplete Freu... therapeutic aut... cyclophosphamid... fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | NCT00107354 | Leukemia Myelodysplastic... | aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo... | 14 Years - | Fred Hutchinson Cancer Center | |
| Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma | NCT00138229 | Melanoma (Skin) | aldesleukin filgrastim therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT01106235 | Stage IV Melano... | therapeutic aut... aldesleukin cyclophosphamid... biopsy | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | NCT00101257 | Ovarian Cancer Peritoneal Cavi... | therapeutic aut... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00639639 | Malignant Neopl... | tetanus toxoid therapeutic aut... therapeutic aut... | 18 Years - | Duke University | |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | NCT00553306 | Recurrent Melan... Stage IV Melano... | therapeutic aut... aldesleukin cyclophosphamid... biopsy immunohistochem... flow cytometry polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | NCT01339663 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... aldesleukin autologous tumo... laboratory biom... immunologic tec... immunohistochem... polymerase chai... therapeutic aut... | 18 Years - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma | NCT00004024 | Brain and Centr... | aldesleukin autologous tumo... muromonab-CD3 sargramostim therapeutic aut... surgical proced... radiation thera... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | NCT00005803 | Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph... | Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT01106235 | Stage IV Melano... | therapeutic aut... aldesleukin cyclophosphamid... biopsy | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045357 | Melanoma (Skin) | therapeutic aut... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00085462 | Melanoma (Skin) | aldesleukin filgrastim gp100-fowlpox v... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00012207 | Leukemia Lymphoma | aldesleukin therapeutic aut... cyclophosphamid... prednisone vincristine sul... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma | NCT00317759 | Melanoma (Skin) | therapeutic aut... fludarabine pho... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | NCT00945269 | Recurrent Melan... Stage III Melan... Stage IV Melano... | therapeutic aut... aldesleukin denileukin dift... biopsy immunohistochem... laboratory biom... polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | NCT00004022 | Melanoma (Skin) | aldesleukin autologous tumo... muromonab-CD3 therapeutic aut... surgical proced... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Biological Therapy in Treating Women With Stage IV Breast Cancer | NCT00027807 | Breast Cancer | Aldesleukin Sargramostim therapeutic aut... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma | NCT00006480 | Neuroblastoma | aldesleukin therapeutic aut... chemotherapy ganciclovir | 1 Year - 17 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer | NCT00020722 | Breast Cancer | therapeutic aut... Ifosfamide, car... Cyclophosphamid... Leukapheresis peripheral bloo... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma | NCT00138229 | Melanoma (Skin) | aldesleukin filgrastim therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma | NCT00046852 | Infection Multiple Myelom... | filgrastim pneumococcal po... therapeutic aut... therapeutic tum... carmustine cyclophosphamid... melphalan bone marrow abl... peripheral bloo... | 18 Years - 80 Years | University of Maryland, Baltimore | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer | NCT00014573 | Brain and Centr... | aldesleukin autologous tumo... filgrastim sargramostim therapeutic aut... carmustine cisplatin cyclophosphamid... paclitaxel autologous bone... conventional su... peripheral bloo... | - 65 Years | Barbara Ann Karmanos Cancer Institute | |
| Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma | NCT00730613 | Brain and Centr... | therapeutic aut... gene expression... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | NCT00005803 | Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph... | Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer | NCT00030342 | Colorectal Canc... Kidney Cancer | recombinant int... sargramostim therapeutic aut... fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045357 | Melanoma (Skin) | therapeutic aut... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00003567 | Brain and Centr... Lymphoma Unspecified Adu... | filgrastim sargramostim therapeutic aut... O6-benzylguanin... carmustine temozolomide in vitro-treate... | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00085462 | Melanoma (Skin) | aldesleukin filgrastim gp100-fowlpox v... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lymphocyte Therapy in Treating Patients With Kidney Cancer | NCT00002589 | Kidney Cancer | aldesleukin muromonab-CD3 therapeutic aut... adjuvant therap... | 16 Years - | National Cancer Institute (NCI) | |
| Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00003567 | Brain and Centr... Lymphoma Unspecified Adu... | filgrastim sargramostim therapeutic aut... O6-benzylguanin... carmustine temozolomide in vitro-treate... | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | NCT00019357 | Unspecified Adu... | aldesleukin therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00079144 | Melanoma (Skin) | NY-ESO-1 peptid... aldesleukin filgrastim incomplete Freu... therapeutic aut... cyclophosphamid... fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Prostate Cancer | NCT00039299 | Prostate Cancer | therapeutic aut... | - | National Cancer Institute (NCI) | |
| Lymphocyte Therapy in Treating Patients With Kidney Cancer | NCT00002589 | Kidney Cancer | aldesleukin muromonab-CD3 therapeutic aut... adjuvant therap... | 16 Years - | National Cancer Institute (NCI) | |
| Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer | NCT01943188 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | stereotactic bo... cyclophosphamid... therapeutic aut... laboratory biom... | 18 Years - | Stanford University | |
| Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia | NCT00003727 | Leukemia | filgrastim recombinant int... sargramostim therapeutic aut... carmustine cyclophosphamid... etoposide gemcitabine hyd... melphalan bone marrow abl... in vitro-treate... | - 120 Years | University of Maryland, Baltimore | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT01005537 | Melanoma (Skin) | aldesleukin therapeutic aut... cyclophosphamid... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00639639 | Malignant Neopl... | tetanus toxoid therapeutic aut... therapeutic aut... | 18 Years - | Duke University | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
